Impact BioMedical, INC. Net Income (Loss) Available to Common Stockholders, Basic
Impact BioMedical, INC. (IBO) reported Net Income (Loss) Available to Common Stockholders, Basic of $4.25 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-12
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was $4.25M.
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$889.00K.
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$962.00K.
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$1.24M.
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$4.34M.
- Impact BioMedical, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$7.05M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.25M 10-Q · filed 2024-11-12 | $3.36M derived: sum of 2 quarters · filed 2024-11-12 | $2.40M 10-Q · filed 2024-11-12 | $1.16M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | -$889.00K 10-Q · filed 2024-08-13 | -$1.85M 10-Q · filed 2024-08-13 | -$3.09M derived: sum of 3 quarters · filed 2024-08-13 | -$4.25M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | -$962.00K 10-Q · filed 2024-05-10 | -$2.20M derived: sum of 2 quarters · filed 2024-05-10 | -$3.36M derived: sum of 3 quarters · filed 2024-11-12 | -$4.46M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$2.40M derived: sum of 2 quarters · filed 2024-11-12 | -$3.50M derived: sum of 3 quarters · filed 2024-11-12 | -$4.34M 10-K · filed 2024-02-20 |
| 2023-09-30 | -$1.16M 10-Q · filed 2024-11-12 | -$2.26M derived: sum of 2 quarters · filed 2024-11-12 | -$3.10M 10-Q · filed 2024-11-12 | -$6.28M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.10M 10-Q · filed 2024-08-13 | -$1.94M 10-Q · filed 2024-08-13 | -$5.12M derived: sum of 3 quarters · filed 2024-08-13 | -$7.29M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$657.00K 10-Q · filed 2024-05-10 | -$4.02M derived: sum of 2 quarters · filed 2024-05-10 | -$6.19M derived: sum of 3 quarters · filed 2024-05-10 | -$6.92M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$5.53M derived: sum of 2 quarters · filed 2024-02-20 | -$6.26M derived: sum of 3 quarters · filed 2024-02-20 | -$7.05M 10-K · filed 2024-02-20 |
| 2022-09-30 | -$2.17M 10-Q · filed 2023-11-13 | -$2.90M derived: sum of 2 quarters · filed 2023-11-13 | -$3.69M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$732.00K 10-Q · filed 2023-10-05 | -$1.41M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |